Thromboembolic events in metastatic testicular cancer treated with cisplatin-based chemotherapy

Table 3 Comparison of metrics between patients with testicular germ cell tumors at our Institution stratified by those who experienced a thromboembolic event and those who did not

	Thromboembolic event
Metric	No (%)	Yes (%)	P value
n	49	19
Age [mean (SD)]	30.9 (7.86)	30.79 (8.67)	0.909
BMI [mean (SD)]	27.87 (6.38)	30.22 (9.25)	0.237
Cigarette smoker = Yes (%)	27 (55.1)	8 (42.1)	0.421
Marijuana use = Yes (%)	13 (26.5)	3 (15.8)	0.526
Side of orchiectomy = Right (%)	27 (55.1)	6 (31.6)	0.107
Pathology = Seminoma (%)	11 (22.4)	8 (42.1)	0.135
Pathologic stage (%)			0.050
I	10 (20.4)	0 (0.0)
II	33 (67.3)	14 (73.7)
III	6 (12.2)	5 (26.3)
Port = Yes (%)	4 (8.2)	3 (15.8)	0.390
Type of chemotherapy (%)
BEP X 3	45 (91.8)	13 (68.4)
BEP X 3 + EP X 1	4 (8.2)	2 (10.5)
EP X 4	0 (0.0)	4 (21.1)
RPLN ≥ 3.0 cm = Yes (%)	10 (20.4)	8 (42.1)	0.123
RPLND = Yes (%)	12 (24.5)	6 (31.6)	0.555
Recurrence after chemotherapy = Yes (%)	3 (6.1)	2 (10.5)	0.614

BMI: Body mass index; BEP: Bleomycin, etoposide, and cisplatin; EP: Etoposide and cisplatin; RPLN: Retroperitoneal lymph node; RPLND: Retroperitoneal lymph node dissection.